Thermo Fisher Scientific reported a strong Q2 2025 performance, with revenues up 3% year-over-year to $10.86 billion, beating analyst estimates. The life sciences solutions segment grew 6%, while analytical instruments declined 3%. The company raised its full-year revenue and adjusted EPS guidance, driven by $300 million in additional cost reductions and easing US-China tariff impacts. CFO Stephen Williamson announced his retirement effective March 2026, with Jim Meyer named successor. Shares surged over 10% following the announcement.